1228392-59-3Relevant articles and documents
Fused tricyclic derivative as FGFR4 inhibitor
-
Paragraph 0223-0228, (2021/05/12)
The present invention provides a fused tricyclic derivative that is the selective inhibitor of fibroblast growth factor receptor 4 (FGFR4), a pharmaceutical composition containing the compound, a method of making the compound and a method of treating cell proliferative diseases, such as cancer, using the compounds of the invention.
FGFR4 INHIBITOR AND USE THEREOF
-
Paragraph 0077; 0083, (2021/07/17)
Disclosed is a compound as a fibroblast growth factor receptor 4 (FGFR4) inhibitor (as shown in formula (I)), and a pharmaceutical composition thereof and a preparation method therefor, as well as the use of same in the treatment of FGFR4-mediated disease
PYRIMIDINE DERIVATIVE, METHOD FOR PREPARING SAME AND USE THEREOF IN MEDICINE
-
Paragraph 0068; 0069, (2019/04/16)
The present invention relates to a pyrimidine derivative, a method for preparing same and use thereof in medicine. In particular, the present invention relates to a pyrimidine derivative represented by general formula (I), a method for preparing same and a pharmaceutically acceptable salt thereof as well as use thereof as a therapeutic agent, in particular as a FGFR4 kinase inhibitor, definitions of each substituent in the general formula (I) being the same as those defined in the description.
FGFR4 inhibitor and application thereof
-
Paragraph 0135; 0146-0148, (2019/03/28)
The invention belongs to the field of medical chemistry, and particularly relates to a novel FGFR4 inhibitor, a medicine composition comprising the inhibitor and a use of the inhibitor or medicine composition as a cancer curative drug.
Quinoline and Isoquinoline Based HDAC Inhibitors and Methods of Use Thereof
-
Paragraph 0173; 0174, (2019/09/16)
The present invention relates to methods of modulating activity of histone deacetylases (HDACs). The present invention also relates to methods of treating HDAC-associated diseases including, but not limited to, cancers, inflammatory disorders, and neurode
Heterocycle type derivative and preparing method and pharmaceutical application thereof
-
Paragraph 0347; 0349-0352, (2018/07/30)
The invention relates to a novel heterocycle type derivative, a preparing method thereof, a medicine composition containing the derivative and application of the heterocycle type derivative as therapeutic agent, particularly an FGFR4 inhibitor. The preferable compound has a good inhibiting effect on FGFR4.
Pyrimidine derivatives as well as preparation method and medical applications thereof
-
Paragraph 0169; 0171; 0173-0175, (2017/12/27)
The invention relates to pyrimidine derivatives as well as a preparation method and medical applications thereof, in particular to pyrimidine derivatives shown as a general formula (I) in the description, a preparation method and medicinal salts thereof and applications of the pyrimidine derivatives and the medicinal salts as therapeutic agents, especially as FGFR4 (fibroblast growth factor receptor 4) kinase inhibitors. Definitions of substituent groups in the general formula (I) are the same as those in the description.
Fibroblast growth factor receptor selective inhibitor and applications thereof
-
Paragraph 0441-0443, (2017/08/23)
The invention discloses a fibroblast growth factor receptor selective inhibitor and applications thereof. The invention provides a compound as shown in a formula (I), and a stereoisomer, a tautomer or pharmaceutically accepted salts thereof, and applicati
CRYSTALLINE FGFR4 INHIBITOR COMPOUND AND USES THEREOF
-
Page/Page column 26-27, (2016/11/02)
A number of crystalline forms of N-(2-((6-(3-(2,6-dichloro-3,5-dimethoxyphenyl)-1-methylureido)pyrimidin-4-yl)amino)-5-(4-ethylpiperazin-1-yl)phenyl)acrylamide are provided. These include a crystalline free base form, a crystalline monohydrochloride salt
PYRIMIDINE FGFR4 INHIBITORS
-
Page/Page column 62-63; 67; 68, (2015/05/05)
Provided herein are compounds of Formula I useful as FGFR4 inhibitors, as well as methods of use of the same.
